MetaADEDB 2.0 @ LMMD
eslicarbazepine acetate
(QIALRBLEEWJACW-INIZCTEOSA-N)
Structure
SMILES
CC(=O)O[C@H]1Cc2ccccc2N(c2c1cccc2)C(=O)N
Type(s)
Approved
Molecular Formula:
C17H16N2O3
Molecular Weight:
296.321
Log P:
3.8290
Hydrogen Bond Acceptor:
4
Hydrogen Bond Donor:
1
TPSA:
72.63
CAS Number(s):
236395-14-5
Synonym(s)
1.
eslicarbazepine acetate
2.
10-acetoxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide
3.
Aptiom
4.
BIA 2-093
5.
BIA-2-093
6.
Zebinix
External Link(s)
MeSHC416835
PubChem Compound179344
BindingDB50240669
ChEBI87016
CHEMBLCHEMBL87992
DrugBankDB09119
DrugCentral4303
KEGGdr:D09612
ZINC7295
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 31
Canada Vigilance: 1
Canada Vigilance
US FAERS
2DizzinessFAERS: 26US FAERS
3Feeling abnormalFAERS: 16US FAERS
4SomnolenceFAERS: 16US FAERS
5HeadacheFAERS: 15US FAERS
6NauseaFAERS: 11US FAERS
7VomitingFAERS: 11US FAERS
8Blood sodium decreasedFAERS: 10US FAERS
9Memory impairmentFAERS: 10US FAERS
10PruritusFAERS: 10US FAERS
11Drug dose omissionFAERS: 9US FAERS
12MalaiseFAERS: 9US FAERS
13Drug dose titration not performedFAERS: 8US FAERS
14FatigueFAERS: 8US FAERS
15OverdoseFAERS: 7US FAERS
16Peripheral swellingFAERS: 6US FAERS
17Product dose omissionFAERS: 6US FAERS
18AgitationFAERS: 5US FAERS
19AstheniaFAERS: 5US FAERS
20Product use in unapproved indicationFAERS: 5US FAERS
21TremorFAERS: 5US FAERS
22VertigoFAERS: 5US FAERS
23AngerFAERS: 4US FAERS
24AuraFAERS: 4US FAERS
25Drug ineffective for unapproved indicationFAERS: 4US FAERS
26EpilepsyFAERS: 4
Canada Vigilance: 1
Canada Vigilance
US FAERS
27HypersensitivityFAERS: 4
Canada Vigilance: 1
Canada Vigilance
US FAERS
28NervousnessFAERS: 4US FAERS
29ParanoiaFAERS: 4US FAERS
30AmnesiaFAERS: 3US FAERS
31AnxietyFAERS: 3US FAERS
32AphasiaFAERS: 3US FAERS
33BradycardiaFAERS: 3US FAERS
34BradyphreniaFAERS: 3US FAERS
35Cerebrovascular accidentFAERS: 3US FAERS
36ChillsFAERS: 3US FAERS
37ErythemaFAERS: 3US FAERS
38Inappropriate schedule of drug administrationFAERS: 3US FAERS
39Inappropriate schedule of product administrationFAERS: 3US FAERS
40LethargyFAERS: 3US FAERS
41Lip swellingFAERS: 3US FAERS
42Mood swingsFAERS: 3US FAERS
43MyalgiaFAERS: 3
Canada Vigilance: 2
Canada Vigilance
US FAERS
44PainFAERS: 3US FAERS
45Stevens-Johnson SyndromeFAERS: 3US FAERS
46Visual ImpairmentFAERS: 3US FAERS
47Weight decreasedFAERS: 3US FAERS
48Abdominal discomfortFAERS: 2US FAERS
49Adams-Stokes SyndromeFAERS: 2US FAERS
50AngioedemaFAERS: 2US FAERS
51AsthmaFAERS: 2US FAERS
52AtaxiaFAERS: 2US FAERS
53Cerebral disorderFAERS: 2US FAERS
54ConstipationFAERS: 2US FAERS
55DementiaFAERS: 2US FAERS
56DiplopiaFAERS: 2US FAERS
57DisorientationFAERS: 2US FAERS
58Drug administration errorFAERS: 2US FAERS
59Drug screen false positiveFAERS: 2US FAERS
60DysphemiaFAERS: 2US FAERS
61EpistaxisFAERS: 2US FAERS
62Erythema MultiformeFAERS: 2US FAERS
63FlushingFAERS: 2US FAERS
64Gait inabilityFAERS: 2US FAERS
65HypersomniaFAERS: 2US FAERS
66LymphadenopathyFAERS: 2US FAERS
67Myoclonic EpilepsyFAERS: 2
Canada Vigilance: 1
Canada Vigilance
US FAERS
68MyoclonusFAERS: 2
Canada Vigilance: 1
Canada Vigilance
US FAERS
69NephrolithiasisFAERS: 2US FAERS
70Pain of skinFAERS: 2US FAERS
71Product use issueFAERS: 2US FAERS
72Respiratory tract congestionFAERS: 2US FAERS
73Status EpilepticusFAERS: 2US FAERS
74StressFAERS: 2US FAERS
75SwellingFAERS: 2US FAERS
76Therapeutic response unexpectedFAERS: 2US FAERS
77ThrombocytopeniaFAERS: 2US FAERS
78Trigeminal NeuralgiaFAERS: 2US FAERS
79Urinary IncontinenceFAERS: 2US FAERS
80Urinary tract infectionFAERS: 2US FAERS
81UrticariaFAERS: 2US FAERS
82WheezingFAERS: 2US FAERS
83AbasiaFAERS: 1US FAERS
84AcneFAERS: 1US FAERS
85AgranulocytosisFAERS: 1US FAERS
86Alcohol withdrawal syndromeFAERS: 1US FAERS
87AlopeciaFAERS: 1US FAERS
88Altered state of consciousnessFAERS: 1US FAERS
89Ammonia increasedFAERS: 1US FAERS
90Ankle FractureFAERS: 1US FAERS
91Anticonvulsant drug level increasedFAERS: 1US FAERS
92ArthralgiaFAERS: 1US FAERS
93Atrioventricular BlockFAERS: 1US FAERS
94BlepharospasmFAERS: 1US FAERS
95Blood glucose increasedFAERS: 1US FAERS
96Blood potassium increasedFAERS: 1US FAERS
97BronchitisFAERS: 1US FAERS
98BronchospasmFAERS: 1US FAERS
99Burning sensationFAERS: 1US FAERS
100Cardiac ArrestFAERS: 1US FAERS
101Cardiac DeathFAERS: 1US FAERS
102Cell DeathFAERS: 1US FAERS
103Change in seizure presentationFAERS: 1US FAERS
104Chest PainFAERS: 1US FAERS
105Chest discomfortFAERS: 1US FAERS
106CholestasisFAERS: 1US FAERS
107ClumsinessFAERS: 1US FAERS
108Cold sweatFAERS: 1US FAERS
109Completed SuicideFAERS: 1US FAERS
110CryingFAERS: 1US FAERS
111Deep Vein ThrombosisFAERS: 1US FAERS
112Depressed Level of ConsciousnessFAERS: 1US FAERS
113Depressed moodFAERS: 1US FAERS
114Diabetes MellitusFAERS: 1US FAERS
115DiscomfortFAERS: 1US FAERS
116Drug effect incompleteFAERS: 1US FAERS
117DysarthriaFAERS: 1US FAERS
118DysgeusiaFAERS: 1US FAERS
119DysuriaFAERS: 1US FAERS
120Emotional disorderFAERS: 1US FAERS
121EnuresisFAERS: 1US FAERS
122EosinophiliaFAERS: 1US FAERS
123Epileptic auraFAERS: 1US FAERS
124Expired product administeredFAERS: 1US FAERS
125Eye InfectionFAERS: 1US FAERS
126Eye inflammationFAERS: 1US FAERS
127Eye painFAERS: 1US FAERS
128Facial PainFAERS: 1US FAERS
129Feeling ColdFAERS: 1US FAERS
130Flat affectFAERS: 1US FAERS
131Focal dyscognitive seizuresFAERS: 1US FAERS
132Full blood count decreasedFAERS: 1US FAERS
133Gamma-Glutamyltransferase IncreasedFAERS: 1US FAERS
134Hand-eye coordination impairedFAERS: 1US FAERS
135HepatitisFAERS: 1US FAERS
136HungerFAERS: 1US FAERS
137HyperphagiaFAERS: 1US FAERS
138HypokinesiaFAERS: 1US FAERS
139Hyponatraemic seizureFAERS: 1US FAERS
140Incorrect dose administeredFAERS: 1US FAERS
141Incorrect route of drug administrationFAERS: 1US FAERS
142InfectionFAERS: 1US FAERS
143Intentional product misuseFAERS: 1US FAERS
144Intercepted drug administration errorFAERS: 1US FAERS
145LacerationFAERS: 1US FAERS
146Lennox-Gastaut syndromeFAERS: 1US FAERS
147LymphopeniaFAERS: 1US FAERS
148MetamorphopsiaFAERS: 1US FAERS
149Mineral deficiencyFAERS: 1US FAERS
150MultimorbidityFAERS: 1US FAERS
151Nephrotic SyndromeFAERS: 1US FAERS
152NeutropeniaFAERS: 1US FAERS
153PalpitationsFAERS: 1US FAERS
154PancreatitisFAERS: 1US FAERS
155PancytopeniaFAERS: 1US FAERS
156PetechiaeFAERS: 1US FAERS
157PhotophobiaFAERS: 1US FAERS
158Poor quality sleepFAERS: 1US FAERS
159Postictal psychosisFAERS: 1US FAERS
160PregnancyFAERS: 1US FAERS
161Product administered to patient of inappropriate ageFAERS: 1US FAERS
162Product use complaintFAERS: 1US FAERS
163PseudomononucleosisFAERS: 1US FAERS
164Serotonin SyndromeFAERS: 1US FAERS
165Simple Partial SeizuresFAERS: 1US FAERS
166Sinus bradycardiaFAERS: 1US FAERS
167Skin irritationFAERS: 1US FAERS
168Slow speechFAERS: 1US FAERS
169StaringFAERS: 1US FAERS
170Sudden deathFAERS: 1US FAERS
171SyncopeFAERS: 1US FAERS
172TachycardiaFAERS: 1US FAERS
173Tension HeadacheFAERS: 1US FAERS
174TensionFAERS: 1US FAERS
175Throat irritationFAERS: 1US FAERS
176TinnitusFAERS: 1US FAERS
177Toxic Epidermal NecrolysisFAERS: 1US FAERS
178TuberculosisFAERS: 1US FAERS
179Urinary RetentionFAERS: 1US FAERS
180Wrong doseFAERS: 1US FAERS
181Wrong scheduleFAERS: 1US FAERS
182Wrong technique in product usage processFAERS: 1US FAERS
183Seizures16920333CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.